Coluracetam


2-Pyrrolidinone-based racetam nootropic and high-affinity choline uptake enhancer

A synthetic racetam derivative developed at Mitsubishi Tanabe Pharma as a high-affinity choline uptake enhancer for Alzheimer’s disease, subsequently repositioned for major depressive disorder with comorbid generalized anxiety disorder, and distinguished from other racetams by a primary mechanism of action centered on choline transporter modulation rather than direct receptor agonism.

Abstract

Coluracetam (MKC-231, BCI-540) is a synthetic nootropic compound of the racetam structural class, characterized by a 2-oxopyrrolidinylacetamide pharmacophore fused to a tetrahydrofuroquinoline ring system, and distinguished from other racetam-class agents (piracetam, aniracetam, pramiracetam, oxiracetam) by a primary mechanism of action centered on the enhancement of high-affinity choline uptake (HACU), the rate-limiting step in acetylcholine biosynthesis. The compound was synthesized at the Mitsubishi Tanabe Pharma Corporation in the early 1990s as part of a medicinal chemistry program targeting cholinergic neurotransmission deficits in Alzheimer’s disease. The Murai et al. (1994) study in ethylcholine aziridinium-treated mice provided the initial demonstration that MKC-231 ameliorated working memory deficits and restored hippocampal acetylcholine levels without producing the tremor, salivation, or hypothermia characteristic of direct cholinomimetic agents such as tacrine [4]. The compound advanced through Phase 2 clinical trials at Mitsubishi Tanabe for Alzheimer’s disease but failed to meet primary efficacy endpoints, and development for that indication was discontinued.

In 2006, BrainCells, Inc. in-licensed coluracetam under the designation BCI-540 and repositioned it for major depressive disorder (MDD) with comorbid generalized anxiety disorder (GAD). However, a pre-specified subgroup analysis in patients with comorbid MDD and GAD demonstrated a 12.2-point improvement on the HAM-D in the three-times-daily dosing cohort compared to 5.5 points in the placebo group (p < 0.008), and a corresponding improvement in anxiety symptoms [5]. The compound was well tolerated in this trial, with a side-effect profile similar to placebo. BrainCells, Inc. subsequently ceased active operations, and no further clinical trials have been reported.

Beyond the cholinergic mechanism, coluracetam has been characterized as a positive modulator of AMPA-type glutamate receptors (an “ampakine” property shared with aniracetam and some other racetams), though this activity is less well characterized than the HACU enhancement and the functional contribution to the in vivo pharmacology is uncertain [6]. The compound is not approved by any regulatory authority for any indication. It is supplied as a research-grade preparation by multiple chemical suppliers and is used in nootropic research contexts. Investigators should obtain analytical confirmation of identity and purity on every lot. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph